Uni-Bio Science Group Limited Announces Poll Results of Extraordinary General Meeting Held on 26 May 2026
Key Highlights for Investors:
- All resolutions at the 26 May 2026 EGM were duly passed by poll, including the adoption of a New Share Option Scheme and the termination of the existing scheme.
- No shareholders were required to abstain from voting, and the resolutions received strong majority support.
- The results may have implications for company management incentives, dilution, and the company’s long-term strategic direction.
Details of the EGM and Voting Results
Uni-Bio Science Group Limited held its Extraordinary General Meeting (EGM) on 26 May 2026. At the meeting, shareholders were asked to vote on three ordinary resolutions:
- Adoption of the New Share Option Scheme
- Termination of the Existing Share Option Scheme
- Approval of the Service Provider Sublimit under the New Scheme
All three resolutions were approved by a large majority:
- For: 771,169,554 votes (94.13%)
- Against: 48,060,000 votes (5.87%)
This level of support signals broad shareholder agreement with the proposed changes.
Important Information for Shareholders
- All Resolutions Passed: The adoption of the new share option scheme and the termination of the previous scheme represent a significant update to the company’s incentive structure.
- Potential Share Price Impact: Changes to the share option scheme may affect future share dilution, management incentives, and the company’s ability to attract and retain key talent. These factors can be price sensitive and may influence investor sentiment.
- No Voting Restrictions: All 5,971,228,147 shares in issue were eligible to vote. No shareholder was required to abstain, and no one indicated opposition in advance.
- Professional Vote Scrutiny: Tricor Investor Services Limited acted as the scrutineer for the vote-taking, ensuring transparency and compliance.
- Board Composition: The Board comprises four executive Directors, two non-executive Directors, and three independent non-executive Directors. All attended the EGM either in person or electronically, demonstrating strong governance and oversight.
Why This Matters
The successful adoption of a new share option scheme is a material event for Uni-Bio Science Group Limited. It reflects the company’s commitment to updating its incentive structures, which can have direct implications for talent retention, corporate governance, and long-term strategy. Investors should carefully consider how the new scheme may affect share dilution and management focus.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should consult their financial advisors before making investment decisions. All information is based on the company’s official announcement as of 26 May 2026.
聯康生物科技集團有限公司：2026年5月26日特別股東大會投票結果詳情
投資者需注意重點：
- 2026年5月26日特別股東大會上，所有決議案均獲得通過，包括採納新購股權計劃及終止現行計劃。
- 無需任何股東棄權，決議案得到壓倒性支持。
- 事件或影響管理層激勵、潛在攤薄及公司長遠策略方向，屬具潛在影響股價的重要消息。
會議及投票詳情
聯康生物科技於2026年5月26日舉行特別股東大會，表決三項普通決議案：
- 採納新購股權計劃
- 終止現行購股權計劃
- 批准新計劃下的服務供應商配額
三項決議案均獲得大比數通過：
- 贊成：771,169,554 票 (94.13%)
- 反對：48,060,000 票 (5.87%)
反映股東對公司激勵政策更新有高度共識。
股東須知要點
- 所有決議通過：新購股權計劃的落實及舊計劃的終止，標誌公司激勵架構的重要變革。
- 潛在股價影響：激勵政策的變更或影響未來攤薄、管理層激勵及吸引人才能力，屬高度敏感事項。
- 無投票限制：全部5,971,228,147股均可投票，無股東須棄權，亦無提前表示反對。
- 專業監票：投票由卓佳證券登記有限公司負責核實，確保公正合規。
- 董事會組成：董事會包括四名執行董事、兩名非執行董事及三名獨立非執行董事，全部親身或以電子方式出席，體現良好管治。
此事對投資者的重要性
新激勵計劃的通過屬於公司重大事件，反映公司積極調整激勵政策，對於人才保留、管治及策略具長遠影響。投資者應留意新計劃對未來股份攤薄及管理層專注度的影響。
免責聲明：本文僅供參考，並不構成任何投資建議。投資者應諮詢專業財務顧問後再作決定。所有資料以公司2026年5月26日之公告為準。
